MetaCap

Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs Lisata Therapeutics (LSTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($982,950 vs $647,451), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDRX+232.56%LSTA-23.17%
+668%+298%-71%
Oct 7, 20261 yearNov 20, 2026
BDRX+307.43%LSTA-15.20%
+678%+315%-48%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDRX versus LSTA key metrics
MetricBDRXLSTA
Share price$1.88$0.8989
Market cap$982.95K$647.45K
1-day change-3.85%-1.22%
YTD return—-51.67%
1-year return—-54.14%
5-year return—-93.89%
P/E ratio (TTM)0.00—
EPS (TTM)$509.89$-28.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$170.00K
Revenue growth (YoY)—-83.00%
Net income (latest FY)—$-16.59M
Operating margin—-10711.18%
Net margin—-9756.47%
52-week high$357.60$76.05
52-week low$1.85$0.85
Distance from 52-week high-99.48%-98.82%
Analyst consensusnonenone
Avg. price target upside+375.20%—
Average volume618.91K13.46K
Shares outstanding524.24K720.27K
Employees1121
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Biodexa Pharmaceuticals American Depositary Shs

BDRX stock →

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About Lisata Therapeutics

LSTA stock →

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

BDRX vs LSTA FAQ

Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or Lisata Therapeutics?

Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $982.95K compared with $647.45K for Lisata Therapeutics (LSTA).

Are Biodexa Pharmaceuticals American Depositary Shs and Lisata Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons